Consideration on pre-clinical pharamacodynamic evaluation of non-alcoholic steatohepatitis innovative drugs
Efficiency in pharmacodynamic study and evaluation is the critical issue in current drug research and development of non-alcoholic steatohepatitis(NASH).Resmetirom,the first marketed medicine for NASH,is approved by pathological surrogate endpoints,meanwhile several clinical trials suspended due to failure to achieve the liver histologic surrogate endpoints.The well-done non-clinical pharmacodynamic study basing on pathological features(ballooning degeneration,lobular inflammation,fibrosis)of NASH,is a great support to the whole research and development projects of new medicines for NASH.In this article,we discussed the necessity and feasibility of the NASH non-clinical pharmacodynamic study combining the clinical trials of NASH drug,the pathological features and the animal models of NASH,in order to facilitate the high-quality research and development of NASH drugs.
万方数据
维普
